Skip to main content
SpringerLink
Log in

Pharmacologic Agents in the Treatment of DM

  • Chapter
Dermatomyositis

  • 1689 Accesses

The cornerstone of therapy is immunosuppressive medication. Corticosteroids, immuno-suppressive agents, high-dose intravenous immunoglobulin (IVIG), and antimalarial drugs are the principal medicines with marked efficacy in the treatment of DM [1–3]. Truly refractory patients may benefit from pulse corticosteroids, followed by tapering of oral prednisone, intravenous immunoglobulin, or cyclosporine A [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Raifman CM, Schaffer FM, Wachsmuth SE. Reversal of chronic polymyositis following intravenous immune serum globin therapy. JAMA 1987; 258: 513–515.

    Google Scholar 

  2. Gelfand E W. The use of intravenous immune globulin in collagen vascular disorders: a potentially new modality of therapy. J Allergy Clin Immunol 1989; 84(4 Pt 2): 613–615.

    Article  PubMed  CAS  Google Scholar 

  3. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immu-noglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993–2000.

    Article  PubMed  CAS  Google Scholar 

  4. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162–168.

    Article  PubMed  CAS  Google Scholar 

  5. Lang BA, Laxer RM, Murphy G, et al. Treatment of dermatomyositis with intravenous gam-maglobulin. Am J Med 1991; 91: 169–172.

    Article  PubMed  CAS  Google Scholar 

  6. Dalakas MC. Intravenous immunoglobulin for dermatomyositis. N Engl J Med 1994; 330: 1392–1393.

    Article  Google Scholar 

  7. Patel SY, Kumararatne DS. From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies. Clin Exp Immunol 2001; 124: 169–171.

    Article  PubMed  CAS  Google Scholar 

  8. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729–1735.

    Article  PubMed  CAS  Google Scholar 

  9. Amemiya K, Semino-Mora C, Granger R P, et al. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000; 94: 99–104.

    Article  PubMed  CAS  Google Scholar 

  10. Yu Z, Lennon VA. Mechanism of intravenous human globin therapy in antibody-mediated autoimmune disease. N Engl J Med 1999; 340: 227–228.

    Article  PubMed  CAS  Google Scholar 

  11. Lutz HU, Stammler P, Jelezarova E, et al. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184–193.

    PubMed  CAS  Google Scholar 

  12. Kazatchkine MD, Kaveri S V. Immunomodulation of autoimmune and inflammatory disease with intravenous immunoglobulin. N Engl J Med 2001; 345: 747–755.

    Article  PubMed  CAS  Google Scholar 

  13. Götterfied I, Seeber A, Anegg B, et al. High dose intravenous immunoglobulin (IVIG) in der-matomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 2000; 10: 29–35.

    Google Scholar 

  14. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis—four year review of nine cases. Arch Dis Child 1995; 72(1): 25–28.

    Article  PubMed  CAS  Google Scholar 

  15. Morita R, Nakano K, Hirano Y, et al. Dramatic effects of high-dose intravenous gammaglobu-lin in each patient with intractable dermatomyositis and polymyositis. No To Hattatsu 1989; 21(6): 523–528 [Japanese].

    PubMed  CAS  Google Scholar 

  16. Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intactable dermatomyositis skin lesions. J Dermatol 1999; 26: 457–459.

    PubMed  CAS  Google Scholar 

  17. Saadeh C, Bridges W, Burwick F. Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South Med J 1995; 88(8): 866–870.

    PubMed  CAS  Google Scholar 

  18. Mastaglia FL, Phillips BA, Zilko PJ. Immunoglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1998; 65: 107–110.

    Article  PubMed  CAS  Google Scholar 

  19. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow-up of intravenous immu-noglobulin infusions in chronic refractory polymyositis: an open study with 35 adult patients. Arthritis Rheum 2002; 46(2): 467–474.

    Article  PubMed  CAS  Google Scholar 

  20. Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci 2003; 24: S256–S259.

    Article  PubMed  Google Scholar 

  21. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 1999; 22: 1479–1497.

    Article  PubMed  CAS  Google Scholar 

  22. Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002; 61: 37–41.

    Article  PubMed  CAS  Google Scholar 

  23. Eshraghi N, Farahmand M, Maerz LL, et al. Adult-onset dermatomyositis, with severe gastrointestinal manifestations: case report and review of the literature. Surgery 1998; 123: 356–358.

    PubMed  CAS  Google Scholar 

  24. Rigby S P, Schott JM, Bliss P, et al. Dilated stomach and weak muscles. Lancet 2000; 356: 1898.

    Article  PubMed  CAS  Google Scholar 

  25. Marie I, Levesque H, Cailleux N, et al. Intravenous immunoglobulin for treatment of gastrointestinal haemorrhage in dermatomyositis. Ann Rheum Dis 2001; 60: 723–724.

    Article  PubMed  CAS  Google Scholar 

  26. Fukunaga E, Kunishigea M, Mitsuia T, et al. Severe dermatomyositis with rhabdomyolysis and paralytic ileus: a case successfully treated with plasmapheresis and intravenous immu-noglobulin. EFNS Eur J Neurol 2002; 9: 687–702.

    Google Scholar 

  27. Ratko TA, Burnett DA, Foulke GE, et al. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995; 273: 457–492.

    Article  Google Scholar 

  28. Jolles S, Hughes J, Whittacker S. Dermatological uses of high-dose intravenous immuno-globulin. Arch Dermatol 1998; 134: 80–86.

    Article  PubMed  CAS  Google Scholar 

  29. Roujeau JC. Dermatomyositis. In: Therapeutique Dermatologique, Dubertret L (ed.), Medecine-Sciences, Flammarion, Paris, 2001; 178–182.

    Google Scholar 

  30. Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neu-rol 2003; 50: 10–15.

    CAS  Google Scholar 

  31. Maillard SM, Wilkinson N, Davidson JE, Murray KJ. The treatment of persistent severe idiopathic inflammatory myositis with anti TNF therapy. Ann Rheum Dis 2002; 61: S143.

    Google Scholar 

  32. Mastaglia FL, Garlepp MJ, Phillips BA, et al. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003; 27(4): 407–425.

    Article  PubMed  Google Scholar 

  33. Hengstman G, van den Hoogen F, van Engelen B, et al. Anti-TNF-α blockade with infliximab (Remicade) in polymyositis and dermatomyositis [abstract]. Arthritis Rheum 2000; 43: S193.

    Google Scholar 

  34. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology 2003; 42: 1566–1568.

    Article  PubMed  CAS  Google Scholar 

  35. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 2008; 47(6): 877–880.

    Article  PubMed  CAS  Google Scholar 

  36. Nzeusseu A, Durez P, Houssiau F, et al. Successful use of infliximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum 2001; 44: S90.

    Google Scholar 

  37. Roddy E, Couriney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab [letter]. Rheumatology 2002; 41: 1194–1195.

    Article  PubMed  CAS  Google Scholar 

  38. Norman R, Greenber RG, Jackson JM. Case report of etanercept in inflammatory dermatoses. J Am Acad Dermatol 2006; 54(Suppl 2): S139–142.

    Article  PubMed  Google Scholar 

  39. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006; 55(6): 982–984.

    Article  PubMed  CAS  Google Scholar 

  40. Saadeh CK. Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents [abstract]. Arthritis Rheum 2000; 43: S193.

    Google Scholar 

  41. Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Pract Res Clin Rheumatol 2004; 18 (3): 429–462.

    PubMed  CAS  Google Scholar 

  42. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin—cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66(4): 807–815.

    Article  PubMed  CAS  Google Scholar 

  43. Oddis C V. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 2000; 12(6): 492–497.

    Article  PubMed  CAS  Google Scholar 

  44. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52(8): 2439–2446.

    Article  PubMed  CAS  Google Scholar 

  45. Ochi S, Nanki T, Takada K, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 2005; 23: 707–710.

    PubMed  CAS  Google Scholar 

  46. Mitsui T, Kuroda Y, Kunishige M, et al. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med 2005; 44(11): 1197–1199.

    Article  PubMed  Google Scholar 

  47. Martín Nalda A, Modesto Caballero C, Arnal Guimeral C, et al. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc) 2006; 127(18): 697–701.

    Google Scholar 

  48. Jorizzo JL. Dermatomyositis: practical aspects. Arch Dermatol 2002; 138: 114–116.

    Article  PubMed  Google Scholar 

  49. Kaplan M. Eculizumab (Alexion). Curr Opin Invest Drugs 2002; 3: 1017–1023.

    CAS  Google Scholar 

  50. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 2006; 33(5): 1021–1026.

    PubMed  Google Scholar 

  51. Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol 1994; 19(4): 367.

    Article  PubMed  CAS  Google Scholar 

  52. Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int J Dermatol 2002; 41: 182–184.

    Article  PubMed  Google Scholar 

  53. Coleman MD. Dapsone: modes of action, toxicity, and possible strategies for increasing patient tolerance. Br J Dermatol 1993; 129: 507–513.

    Article  PubMed  CAS  Google Scholar 

  54. Dalakas MC, Hohfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971–982.

    Article  PubMed  CAS  Google Scholar 

  55. Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002; 41(1): 7–13.

    Article  CAS  Google Scholar 

  56. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile der-matomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 2000; 19: 138–141.

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

(2009). Pharmacologic Agents in the Treatment of DM. In: Dermatomyositis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79313-7_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-79313-7_39

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-79312-0

  • Online ISBN: 978-3-540-79313-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation